Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 26, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Implementation Benchmark of Tumor-Agnostic Eligibility Signals Across Routine Comprehensive Genomic Profiling

Shinya Kajiura1, Naohiko Nakamura1, Ryuji Hayashi1

  • 1Department of Medical Oncology and Palliative Medicine, Toyama University Hospital, 2630 Sugitani, Toyama 930-0194, Toyama, Japan.

Current Oncology (Toronto, Ont.)
|June 25, 2026
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Facility-level JSMO specialist availability and reconstructable treatment-process measures in colorectal cancer using C-CAT data.

International journal of clinical oncology·2026
Same author

Association of Participation in a National Standardized Palliative Care Education Program With Self-Reported Prior Palliative Care Team Consultation: A Single-Center Staff Survey During Early Program Implementation.

Journal of cancer education : the official journal of the American Association for Cancer Education·2026
Same author

Cumulative multidisciplinary team messages and home death after palliative care unit discharge in advanced cancer: a prospective regional implementation cohort study.

International journal of clinical oncology·2026
Same author

Three-month follow-up of high-dose intravenous iron monotherapy for cancer-related anemia in an ESA-free oncology setting: a real-world cohort study.

International journal of clinical oncology·2026
Same author

Injectable Opioid Use in Home Palliative Care: A Pilot Survey of Multidisciplinary Role Sharing and Readiness.

Journal of palliative medicine·2026
Same author

Observed RET-Positive Findings Across Routine Comprehensive Genomic Profiling Platforms in Japan: A Nationwide Descriptive Benchmark.

Cancers·2026

Realistic benchmarks for tumor-agnostic eligibility signals in precision oncology are crucial. This study establishes nationwide frequencies for key biomarkers from comprehensive genomic profiling (CGP) in Japan.

Area of Science:

  • Oncology
  • Genomics
  • Biomarker Discovery

Background:

  • Precision oncology relies on identifying patients eligible for targeted therapies.
  • Comprehensive genomic profiling (CGP) is increasingly used to detect tumor-agnostic biomarkers.
  • Establishing real-world benchmarks for these signals is essential for routine clinical practice.

Purpose of the Study:

  • To establish realistic, nationwide benchmarks for tumor-agnostic eligibility signals detected via CGP in Japan.
  • To analyze the frequency of specific biomarkers (MSI-H, TMB-H, NTRK, RET, ERBB2, ALK, BRAF V600E) in a large real-world cohort.
  • To provide a platform-aware interpretation of these signals in routine CGP.

Main Methods:

  • Retrospective analysis of anonymized nationwide data from Japan's Center for Cancer Genomics and Advanced Therapeutics (C-CAT).
Keywords:
C-CATJapancomprehensive genomic profilingimplementation benchmarkliquid biopsyprecision oncologyreal-world datatumor-agnostic biomarker

More Related Videos

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology
11:20

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology

Published on: March 21, 2018

Related Experiment Videos

Last Updated: Jun 26, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology
11:20

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology

Published on: March 21, 2018

  • Inclusion of 97,343 cases tested across five routine CGP platforms.
  • Categorization into 12 organ groups and analysis of primary (MSI-H, TMB-H, NTRK, RET, ERBB2) and expanded (ALK, BRAF V600E) eligibility signal sets.

    • Main Results:

    • The primary strict approved set endpoint was observed in 14.4% of cases (14,005/97,343).
    • The expanded practical set endpoint was observed in 16.3% of cases (15,911/97,343), adding 2.0 percentage points.
    • Microsatellite Instability-High (MSI-H) and Tumor Mutational Burden-High (TMB-H) were the most frequent signals; fusions/rearrangements (NTRK, RET) were rare. Signals varied by organ group and platform.

    Conclusions:

    • This nationwide benchmark provides practical interpretation of tumor-agnostic eligibility signals in routine CGP practice in Japan.
    • Observed frequencies reflect real-world implementation signals, not biological prevalence or treatment benefit.
    • The data supports the interpretation of CGP results for precision oncology decision-making.